meRfi®-GM
Irritable Bowel Syndrome (IBS)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Rome criteria defines 26 distinct adult functional gastrointestinal disorders (FGIDs), most well-known are irritable bowel syndrome (IBS) and
Irritable bowel syndrome (IBS) is a functional disorder of the intestine whose pathophysiology is still only very incompletely understood. The prevalence of IBS is high afunctional dyspepsia (FD)nd is reported to be 4%.
Those affected suffer from abdominal pain, bloating, flatulence…
References (Sources)
- Advancements in drug development for diarrhea-predominant irritable bowel syndrome (IBS)
- Development and validation of the Rome IV diagnostic questionnaire for adults
- Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial
- Functional bowel disorders
- Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome
- Spotlight on Transition in Patients With Inflammatory Bowel Disease: A Systematic ReviewReview
- The functional gastrointestinal disorders and the Rome III process